has developed and commercializes two approved
complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH...) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved
complement inhibitor to treat anti... -
Voir cette offre d'emploi